Nuvation Bio (NUVB) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvation Bio (NUVB) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 32.8% versus a loss of 37.2%. Over five years, OCUL leads with a -35.4% price change compared with -49.1% for NUVB. Nuvation Bio is the larger company by market cap ($1.71 billion vs $1.59 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NUVB | OCUL |
|---|---|---|
| Share price | $4.86 | $7.23 |
| Market cap | $1.71B | $1.59B |
| 1-day change | -0.41% | -1.50% |
| YTD return | -45.76% | -40.44% |
| 1-year return | +32.79% | -37.24% |
| 5-year return | -49.11% | -35.39% |
| EPS (TTM) | $-0.44 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.75 | $16.44 |
| 52-week low | $3.36 | $6.23 |
| Distance from 52-week high | -50.15% | -56.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +167.49% | +274.69% |
| Average volume | 5.65M | 2.78M |
| Shares outstanding | 350.12M | 219.62M |
| Employees | 305 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NUVB has outperformed OCUL by 70.0 percentage points over the past year.
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
NUVB vs OCUL FAQ
Which is bigger, Nuvation Bio or Ocular Therapeutix?
Nuvation Bio (NUVB) is larger, with a market capitalization of $1.71B compared with $1.59B for Ocular Therapeutix (OCUL).
Which stock has performed better over the past year, NUVB or OCUL?
NUVB returned +32.79% over the past 12 months, compared with -37.24% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Nuvation Bio and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.